The protective effects of Cilostazol on indomethacin induced gastric ulcer in rat model

Abstract

Introduction: Gastric ulcer is the most common gastrointestinal tract disorder, representing about 20% of peptic ulcers. To examine the preventive impact of Cilostazol on histology, gastric ulcer severity, inflammatory and oxidative stress markers (TNF-alpha, myeloperoxidase and Malondialdehyde) in an indomethacin-induced gastric ulcer model. Method: 50 albino male rates, each with 10 (N=10): Group A: Oral Indomethacin vehicles (normal saline0.9% and tween80) as positive control group. Group B: Indomethacin 60mg/kg orally through oral gavage as negative control. Group C: Omeprazole 20mg/kg gavage 1 hour before 60mg/kg oral Indomethacin. Group D: Cilostazol 10mg/kg via gavage tube 60mg/kg Indomethacin orally 1 hour before. Results: Cilostazol 10 mg/kg pretreatment groups exhibit a substantial (p0.01) decrease in stomach ulcer severity and histopathological damage score. Pretreated groups with cilostazol 10mg/kg reduced inflammatory indicators (TNF-alpha and Myeloperoxidase) and oxidative stress marker (Malondialdehyde), comparable to the reference medication. Conclusion: Cilostazol with cilostazol  1 hour before indomethacin administration shows a reduction and improvement in the damaging effect of indomethacin, both drugs were equally effective and show similar efficacy as standard omeprazole drug by a decrease in oxidative stress status manifested by a reduction in lipid peroxidation indicator marker as well as reduction in pro-inflammatory cytokine level and leukocyte recruitment indicator marker.